Schinke, Carolina

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

Rasche, L., Chavan, S. S., Stephens, O. W., Patel, P. H., Tytarenko, R., Ashby, C., Bauer, M., Stein, C., Deshpande, S., Wardell, C., et al. (2017) · Nature Communications

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 417

Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis

Mazahreh, F., Mazahreh, L., Schinke, C., Thanendrarajan, S., Zangari, M., Shaughnessy, J. D., Zhan, F., van Rhee, F., & Al Hadidi, S. (2023) · Blood Advances

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 142

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma

Boyle, E. M., Deshpande, S., Tytarenko, R., Ashby, C., Wang, Y., Bauer, M. A., Johnson, S. K., Wardell, C. P., Thanendrarajan, S., Zangari, M., et al. (2021) · Nature Communications

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 128

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study.

Chari, A., Touzeau, C., Schinke, C., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Morillo, D., Martinez-Chamorro, C., et al. (2025) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 116

Deciphering the genetics and mechanisms of predisposition to multiple myeloma

Went, M., Duran-Lozano, L., Halldorsson, G. H., Gunnell, A., Ugidos-Damboriena, N., Law, P., Ekdahl, L., Sud, A., Thorleifsson, G., Thodberg, M., et al. (2024) · Nature Communications

Multiple Myeloma Research and TreatmentsGenetic Associations and Epidemiology

Cited by 30

Symptoms, Functioning, and Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab: Updated Patient-Reported Outcomes from the Phase 1/2 MonumenTAL-1 Study

Schinke, C., Touzeau, C., Oriol, A., Mateos, M.-V., Stevens, D. A., Rasche, L., Qin, X., Kato, K., Ming, T., Katz, E. G., et al. (2023) · Blood

Multiple Myeloma Research and TreatmentsCancer survivorship and care

Cited by 6